Faeth Therapeutics, Inc.
FTH
Positions held
Your positionsFTH isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $661.77M | Enterprise value | $475.92M | Trailing P/E | — | Forward P/E | -5.70 |
| PEG | — | Price / book | 3.83 | Beta | -0.29 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -2.0% | ROA | -20.8% | Debt / equity | 0.00 |
| Current ratio | 19.69 | Free cash flow | $855,125 | Analyst recommendation | strong_buy | Mean target | $56.67 |
| 52w high | $42.14 | 52w low | $7.45 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$16.0M | -$170M | -$4.7M | -$4.6M | -$4.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$18.4M | -$171M | -$5.0M | -$4.9M | -$5.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$21.1M | -$30.2M | -$34.1M | -$48.6M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$22.3M | -$31.7M | -$37.1M | -$50.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Faeth Therapeutics' PIK-201 Readout to Serve as Major Inflection Point, Oppenheimer Says
2026-10-07 · Sensei Biotherapeutics Highlights PIKTOR Strategy Ahead of Endometrial Trial Readout
2026-09-17 · Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of Directors
2026-09-16 · Guggenheim Initiates Faeth Therapeutics at Buy With $70 Price Target
2026-09-09 · TD Cowen Initiates Coverage on Faeth Therapeutics With Buy Rating
2026-09-01 · What Makes Faeth Therapeutics, Inc. (FTH) a Strong Momentum Stock: Buy Now?
2026-09-01 · Faeth Therapeutics to Participate in Upcoming September Investor Conferences
2026-08-28 · Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-24 · Wall Street Analysts Predict a 72.22% Upside in Faeth Therapeutics, Inc. (FTH): Here's What You Should Know
2026-08-21 · Needham Initiates Faeth Therapeutics at Buy With $56 Price Target
2026-08-17 · Faeth Therapeutics Gets US FDA Fast Track Designation for Endometrial Cancer Drug Combination
Price (daily)
Full chart · RSI · MACD · patterns